This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZP PTH (Daily)

Zosano Pharma Corporation

Drug Names(s): ZP-PTH, Macroflux PTH, PTH 1-34 patch, Teribone patch

Description: ZP PTH (Daily) is the daily patch of ZP PTH (Weekly).

ZP PTH patch delivers PTH 1-34, teriparatide (PTH), a compound that stimulates formation of new bone and reduces the risk of fractures. The titanium microneedle patch delivery technology transmits the drug into the superficial skin layers through a self-administered applicator.

Deal Structure: Zosano and Eli Lilly
In December 2014, Zosano Pharma and Eli Lilly announced that they have entered into an exclusive agreement to develop ZP-PTH. Under the terms of the agreement, Zosano has granted Lilly an exclusive worldwide license to commercialize ZP-PTH. Lilly will make an equity investment of up to $15 million in Zosano concurrent with the consummation of Zosano's initial public offering of equity securities, and additionally make payments upon achievement of certain regulatory and sales milestones totaling up to $300 million for regulatory approvals and up to $125 million for sales milestones. Zosano is also eligible to receive double-digit royalties on sales of products in major markets and will receive reimbursement of all manufacturing costs.

Pending successful clinical testing outcomes and regulatory approval of ZP-PTH, Lilly will be responsible for commercialization of the product. Zosano will be responsible for funding and developing the product,...See full deal structure in Biomedtracker

ZP PTH (Daily) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug